The most commonly reported side effects of caplacizumab include product use in unapproved indication, off label use, and adamts13 activity decreased, based on 1,692 FDA adverse event reports from 2019 to 2025.
Percentages show how often each reaction appears relative to total reports for caplacizumab.
These are voluntary reports and do not establish that caplacizumab caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside caplacizumab. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
58.0% of caplacizumab adverse event reports involve female patients and 25.6% involve male patients. The largest age group is adult at 81%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking caplacizumab when the adverse event was reported.
Showing 15 of 41 indications
Caplacizumab is sold under the brand name Cablivi.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.